

**2013 ICD-9-CM Casefinding List: Short Version**

| <b>2013 Comprehensive ICD-9-CM* Casefinding Code List for Reportable Tumors</b> |  |
|---|--|
| <b>ICD-9-CM code*</b>   | <b>Explanation of ICD-9-CM code*</b>   |
| 140._ – 172._, 174._<br>– 209.36, 209.7   | Malignant neoplasms stated or presumed to be primary (of specified sites), and certain specified histologies                   |
| 173.00, 173.09,<br>173.10, 173.19   | Unspecified and other specified malignant neoplasm of skin of lip and eyelid, including canthus                                |
| 173.20, 173.29,<br>173.30, 173.39   | Unspecified and other specified malignant neoplasm of ear and skin of other and unspecified parts of face                      |
| 173.40, 173.49,<br>173.50, 173.59   | Unspecified and other specified malignant neoplasm of scalp and skin of neck and skin of trunk, except scrotum                 |
| 173.60, 173.69,<br>173.70, 173.79   | Unspecified and other specified malignant neoplasm of skin of upper limb, including shoulder and lower limb, including hip     |
| 173.80, 173.89,<br>173.90, 173.99   | Unspecified and other specified malignant neoplasm of other specified sites of skin and site unspecified                       |
| 225.0 – 225.9   | Benign neoplasm of brain and spinal cord neoplasm  |
| 227.3, 227.4  | Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland   |
| 228.02  | Hemangioma; of intracranial structures   |
| 228.1   | Lymphangioma, any site   |
| 230.0 – 234.9   | Carcinoma in situ  |
| 237.0 – 237.1   | Neoplasm of uncertain behavior of endocrine glands and nervous system: pituitary gland, craniopharyngeal duct and pineal gland |
| 237.5, 237.6, 237.9   | Neoplasm of uncertain behavior [borderline] of brain, spinal cord and meninges and unspecified parts of nervous system         |
| 238.4   | Polycythemia vera (9950)   |
| 238.6   | Plasma cells   |
| 238.7_  | Other lymphatic and hematopoietic tissues  |
| 239.6, 239.7  | Neoplasms of unspecified nature, brain, other parts nervous system   |
| 273.3   | Macroglobulinemia  |
| 277.89  | Other specified disorders of metabolism  |
| 288.4   | Hemophagocytic syndrome (9751, 9754)   |
| 289.6   | Familial polycythemia  |

**The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.**

| <b>2013 SUPPLEMENTARY LIST #1 ICD-9-CM* CODES THAT SHOULD BE FOLLOWED BY OR ASSOCIATED WITH A NEOPLASM CODE</b> |   |
|---|---|
| <b>ICD-9-CM code*</b>   | <b>Explanation of ICD-9-CM code*</b>                            |
| 258.0_  | Polyglandular activity in multiple endocrine adenomatosis [MEN] |
| 284.2   | Myelophthisis   |
| 285.22  | Anemia in neoplastic disease                                    |
| 289.83  | Myelofibrosis (9961/3)  |
| 331.7   | Cerebral degeneration in diseases classified elsewhere          |

| 2013 SUPPLEMENTARY LIST #1 ICD-9-CM* CODES THAT SHOULD BE FOLLOWED BY OR ASSOCIATED WITH A NEOPLASM CODE |   |
|--|---|
| ICD-9-CM code*   | Explanation of ICD-9-CM code*   |
| 336.3  | Myelopathy in other diseases classified elsewhere                           |
| 357.3  | Polyneuropathy in malignant disease   |
| 358.1  | Myasthenic syndromes in other diseases classified elsewhere                 |
| 358.31   | Eaton-Lambert syndrome in neoplastic disease                                |
| 511.81   | Malignant pleural effusion  |
| 512.82   | Secondary spontaneous pneumothorax  |
| 731.1_   | Osteitis deformans in diseases classified elsewhere                         |
| 731.3  | Major osseous defect  |
| 789.51   | Malignant ascites   |
| V07.5_   | Prophylactic use of agents affecting estrogen receptors and estrogen levels |
| V58.42   | Aftercare following surgery for neoplasm                                    |

**NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm.**

Experience in the SEER registries has shown that using the supplementary list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.

| 2013 SUPPLEMENTARY LIST #2 ICD-9-CM* CODE LIST TO SCREEN FOR CANCER REGISTRY CASES NOT IDENTIFIED BY OTHER CODES |  |
|--|--|
| ICD-9-CM code*   | Explanation of ICD-9-CM code*  |
| 042  | Acquired Immunodeficiency Syndrome (AIDS)  |
| 079.4, 079.5_  | Human papillomavirus; Retrovirus (HTLV, types I, II and 2)   |
| 173.01, 173.02, 173.11, 173.12   | Basal and squamous cell carcinoma of skin of lip and eyelid, including canthus                                       |
| 173.21, 173.22, 173.31, 173.32   | Basal and squamous cell carcinoma of ear and skin of other and unspecified parts                                     |
| 173.41, 173.42, 173.51, 173.52   | Basal and squamous cell carcinoma of scalp and skin of neck and skin of trunk, except scrotum                        |
| 173.61, 173.62, 173.71, 173.72   | Basal and squamous cell carcinoma of skin of upper limb, including shoulder and lower limb, including hip            |
| 173.81, 173.82, 173.91, 173.92   | Basal and squamous cell carcinoma of other specified sites of skin and site unspecified                              |
| 209.40 – 209.69  | Benign carcinoid tumors  |
| 210.0 – 229.9  | Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 228.02, and 228.1, which are listed in the Reportable list)  |
| 235.0 – 239.9  | Neoplasms of uncertain behavior (except for 237.0, 237.1, 237.5, 237.6, 237.9, 238.4, 238.6, 238.7_, 239.6, 239.7) , |
| 249.20   | Secondary diabetes with hypersmolarity   |
| 273.0, 273.1, 273.2, 273.8, 273.9  | Disorders of plasma protein metabolism   |
| 277.88   | Tumor lysis syndrome (following neoplastic chemotherapy)   |

| 2013 SUPPLEMENTARY LIST #2 ICD-9-CM* CODE LIST TO SCREEN FOR CANCER REGISTRY CASES NOT IDENTIFIED BY OTHER CODES |   |
|--|---|
| ICD-9-CM code*   | Explanation of ICD-9-CM code*   |
| 279.02, 279.03, 279.05, 279.12   | Select IgM immunodeficiency and other immunoglobulin deficiencies<br><i>Note: Associated with lymphoproliferative disorders</i> |
| 279.2, 279.3   | Combined and unspecified immunity deficiency  |
| 279.41, 279.49   | Autoimmune lymphoproliferative syndrome   |
| 279.50 – 279.53  | Graft-versus host disease   |
| 279.8, 279.9   | Other and unspecified disorders involving the immune mechanism  |
| 284.1_   | Pancytopenia  |
| 284.81 – 284.9   | Other and unspecified aplastic anemias  |
| 285.0  | Sideroblastic anemia  |
| 285.3  | Anemia due to antineoplastic chemotherapy   |
| 287.39, 287.49, 287.5  | Other primary, secondary and unspecified thrombocytopenia   |
| 288.03   | Drug induced neutropenia  |
| 288.3  | Eosinophilia  |
| 289.89, 289.9  | Other specified diseases of blood and blood forming organs  |
| 323.81   | Other causes of encephalitis and encephalomyelitis  |
| 337.9  | Unspecified disorders of autonomic nervous system   |
| 338.3  | Neoplasm related pain (acute)(chronic)  |
| 352.9  | Unspecified disorder of cranial nerves  |
| 353.8  | Other nerve root and plexus disorders   |
| 516.5  | Adult pulmonary Langerhans cell histiocytosis   |
| 569.44   | Dysplasia of anus (Anal intraepithelial neoplasia [AIN I and II])   |
| 602.3  | Dysplasia of prostate (Prostatic intraepithelial neoplasia [PIN I and II])  |
| 622.1_   | Dysplasia of cervix (CIN I, II and unspecified)   |
| 623.0  | Dysplasia of vagina (Vaginal intraepithelial neoplasia [VAIN I and II])   |
| 624.0_   | Dystrophy of vulva (Vulvar intraepithelial neoplasia [VIN I and II])  |
| 630  | Hydatidiform mole   |
| 648.9_   | Other current conditions classifiable elsewhere   |
| 713.8  | Arthropathy associated with other conditions classified elsewhere   |
| 728.9  | Unspecified disorder of muscle, ligament, and fascia  |
| 733.1_   | Pathologic fracture   |
| 758.0  | Down's Syndrome   |
| 780.79   | Neoplastic (malignant) related fatigue  |
| 785.6  | Enlargement of lymph nodes  |
| 789.51   | Malignant ascites   |
| 790.93   | Elevated prostate specific antigen (PSA)  |
| 791.9  | Other non specific findings on examination of urine   |
| 792.0, 792.2, 792.4, 792.9   | Non specified abnormal findings in specified and unspecified body structures  |
| 793.11   | Solitary pulmonary nodule   |
| 793.8_   | Nonspecific (abnormal) findings on radiological and examination of body structure (breast)                                      |
| 795.0_, 795.1_   | Papanicolaou smear of cervix, vagina, anus and other with cytologic   |

| <b>2013 SUPPLEMENTARY LIST #2 ICD-9-CM* CODE LIST TO SCREEN FOR CANCER REGISTRY CASES NOT IDENTIFIED BY OTHER CODES</b> |   |
|---|---|
| <b>ICD-9-CM code*</b>   | <b>Explanation of ICD-9-CM code*</b>  |
| 795.4, 796.7_   | evidence of malignancy  |
| 795.8_  | Abnormal tumor markers  |
| 962.1, 963.1  | Poisoning by hormones ,antineoplastic, immunosuppressive drugs  |
| 990   | Effects of radiation, unspecified   |
| 996.54  | Mechanical complication of other specified prosthetic device, implant, and graft-due to breast prosthesis     |
| 996.85  | Complication of transplanted organ  |
| 999.3_  | Other infection due to central venous catheter, transfusion, infusion   |
| E858.0 – E858.2   | Accidental poisonings   |
| E873.2  | Failure in dosage, overdose of radiation in therapy   |
| E878.0  | Abnormal reaction of surgical operation with transplant of whole organ  |
| E879.2  | Overdose of radiation given during therapy  |
| E930.7  | Adverse reaction of antineoplastic therapy-Antineoplastic antibiotics   |
| E932.1  | Adverse reaction to antineoplastic therapy  |
| E933.1  | Adverse effect of immunosuppressive drugs   |
| V10.0_ – V10.9_   | Personal history of malignancy  |
| V12.41  | Personal history of benign neoplasm of the brain  |
| V13.89  | Personal history of unspecified malignant neoplasm and history of in-situ neoplasm of other site              |
| V15.22  | Personal history of undergoing in utero procedure during pregnancy  |
| V15.3   | Other personal history presenting hazards to health or radiation  |
| V16._   | Family history of malignant neoplasm  |
| V42.81, V42.82  | Organ or tissue replaced by transplants   |
| V51.0   | Encounter for breast reconstruction following mastectomy  |
| V52.4   | Fitting and adjustment of prosthetic device and implant (breast)  |
| V54.2_  | Aftercare for healing pathologic fracture   |
| V58.0, V58.1_   | Encounter for radiation, chemotherapy and immunotherapy   |
| V66.1, V66.2, V66.7   | Convalescence and palliative care   |
| V67.1, V67.2  | Follow up examinations  |
| V71.1   | Observation for suspected malignant diseases  |
| V72.83  | Other specified pre-operative examination   |
| V76._   | Special screening for malignant neoplasms   |
| V78.8, V78.9  | Other and unspecified disorders of blood and blood forming organs   |
| V86._   | Estrogen receptor status  |
| V87.41, V87.43, V87.46  | Personal history of drug therapy: antineoplastic chemotherapy, estrogen therapy and immunosuppression therapy |

The following codes are associated with the paraneoplastic syndrome. Paraneoplastic syndrome by itself is not cancer. It's a disease or symptom that is the consequence of cancer but is not due to the local presence of cancer cells. A paraneoplastic syndrome may be the first sign of cancer. These codes have been removed from the supplemental list and are now in their own list.

| ICD-9-CM Code* | Explanation of ICD-9-CM Code*                               |
|----------------|---|
| 253.6          | Syndrome of inappropriate secretion of antidiuretic hormone |
| 259.2          | Carcinoid syndrome  |
| 259.8          | Other specified endocrine disorders                         |
| 275.42         | Hypercalcemia   |
| 379.5_         | Nystagmus and other irregular eye movements                 |
| 686.01         | Pyoderma gangrenosum  |
| 694.4          | Pemphigus   |
| 695.89         | Other specified erythematous conditions                     |
| 701.2          | Acquired acanthosis nigricans                               |
| 710.3          | Dermatomyositis   |
| 710.4          | Polymyositis  |

*\*International Classification of Diseases, 9<sup>th</sup> Revision, Clinical Modification, Sixth Edition, 2013*